Press Releases April 23, 2026 04:30 PM

Nano Dimension to Host Q1 2026 Financial Results Conference Call

Nano Dimension announces Q1 2026 financial results conference call scheduled for May 7, 2026.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
NNDM

Nano Dimension Ltd., a Nasdaq-listed digital manufacturing technology company, announced it will hold a conference call on May 7, 2026 to discuss its Q1 2026 financial results ending March 31, 2026. The company serves sectors such as defense, aerospace, automotive, electronics, and medical devices by providing advanced digital manufacturing solutions focused on onshoring, national security, product customization, IP security, and sustainable manufacturing.

Nano Dimension to Host Q1 2026 Financial Results Conference Call
NNDM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nano Dimension will host a Q1 2026 financial results conference call on May 7, 2026.
  • The company delivers digital manufacturing technologies to sectors including defense, aerospace, automotive, electronics, and medical devices.
  • Focus areas include onshoring, national security, product customization, IP security, and sustainable manufacturing.
  • Market and economy sectors impacted include advanced manufacturing, defense, aerospace, automotive, electronics, and medical device industries.

Call to Be Held Thursday, May 7, 2026 at 4:30 PM ET

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM), a leader in digital manufacturing solutions, today announced it will host a conference call and webcast to discuss its Q1 2026 financial results for the period ended March 31, 2026.

Conference Call Information

Date: Thursday, May 7, 2026
Time: 4:30 p.m. ET

Pre-Registration Link for Dial-In Access
Participants can pre-register for the conference call here in order to receive dial in information.

Dial-In Access
Those unable to pre-register may join the call by dialing:

U.S. Dial-in: 1-844-695-5517
International Dial-in: 1-412-902-6751
Israel Toll Free: 1-80-9212373

Access via Webcast
The conference call will be broadcast live (listen only) and can be replayed shortly after the conclusion of the call via the webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZaodVpNh

Participants are advised to log in at least 10 minutes prior to the call.

About Nano Dimension Ltd.
Driven by strong trends in onshoring, national security, and increasing product customization, Nano Dimension Ltd. (Nasdaq: NNDM) delivers advanced Digital Manufacturing technologies to the defense, aerospace, automotive, electronics, and medical devices industries, enabling rapid deployment of high-mix, low-volume production with IP security and sustainable manufacturing practices.

For more information, please visit https://www.nano-di.com/.

Contacts:
Investors: Purva Sanariya
Director, Investor Relations
ir@nano-di.com

Media: Samuel Manning
Principal Manager, External Communications
press@nano-di.com


Risks

  • Financial results might not meet market expectations, creating volatility in stock price; impacts investors and financial markets.
  • Market adoption and demand shifts in advanced digital manufacturing technologies could affect future growth; impacts manufacturing and tech sectors.
  • Geopolitical or supply chain disruptions related to sectors served (defense, aerospace) could impact operations; affects global industrial and defense markets.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026